Protecting dogs and cats against the Australian paralysis tick, (Acari: Ixodidae): A review of the Australian acaricide registration process.

Tick control is mainly achieved through the use of effective ectoparasiticides that can be either dermally or systemically distributed in/on the host. Before any acaricide can be legally made available to veterinarians and pet owners, it must demonstrate efficacy in a series of well-designed dose confirmation studies. The data generated during these studies are then reviewed by government regulators and used for the registration of the acaricide.

Ixodes holocyclus Tick-Transmitted Human Pathogens in North-Eastern New South Wales, Australia.

A group of 14 persons who live in an area of Australia endemic for the Australian paralysis tick, , and who were involved in regularly collecting and handling these ticks, was examined for antibodies to tick-transmitted bacterial pathogens. Five (36%) had antibodies to , the causative agent of Q fever and three (21%) had antibodies to spotted fever group (SFG) rickettsiae ( spp). None had antibodies to , , , or (Lymedisease) suggesting that they had not been exposed to these bacteria.

A randomized controlled trial of the efficacy of orally administered fluralaner (Bravecto™) against induced Ixodes holocyclus (Australian paralysis tick) infestations on dogs.

Background: Ixodes holocyclus ticks are a frequently fatal threat to dogs in eastern Australia. These ticks secrete a neurotoxin that can produce an ascending paralysis after 72 h attachment that can lead to death in affected animals. Fluralaner is a potent systemic acaricide with immediate and persistent efficacy for tick control including evidence of 100% efficacy against Ixodes ricinus ticks within 72 h.